News

Development Protein A (DPA) is a novel therapeutic biologic designed for inhaled administration. In phase I clinical studies, the DPA solution is administered using a continuous-output nebulizer. In ...
About YUTREPIA™ (treprostinil) Inhalation Powder YUTREPIA is an inhaled dry-powder formulation of treprostinil delivered through a convenient, low-effort, palm-sized device.
YUTREPIA is delivered as an inhaled dry-powder formulation through a compact, low-effort device. Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire.
YUTREPIA is an inhaled dry-powder formulation of treprostinil delivered through a convenient, low-effort, palm-sized device. YUTREPIA was designed using Liquidia’s PRINT® technology, which enables the ...
The increase in respiratory diseases worldwide, coupled with the potential for systematic drug delivery, has led to a shifting landscape within inhaled drug delivery. As an alternative to pressurised ...
The BTS/SIGN/NICE have recently published updated guidance for the treatment of asthma.1 The guideline advises that inhaler choice should be based on the lowest environmental impact among suitable ...
YUTREPIA is an investigational, inhaled dry-powder formulation of treprostinil delivered through a convenient, low-effort, palm-sized device. In August 2024, the FDA issued tentative approval of ...
In the present cohort study, the researchers compared the effectiveness and safety of two single-inhaler triple therapies for COPD — budesonide-glycopyrrolate-formoterol (administered twice ...
To overcome these problems, Mannkind developed MNKD-201, a dry powder inhaled formulation of nintedanib that delivers the medication directly to the lungs. According to Wassim Fares, Mannkind’s senior ...
Howard Burnett, Vice President, Global Pulmonary Category, Aptar Pharma, stated, “ The CHI team brings deep knowledge, experience and innovation to the dry powder inhaler landscape.
Dry Powder Inhaler Market The global dry powder inhaler market is on a steady growth path, with a projected valuation of USD 20.83 billion in 2024. The market is expected to expand significantly, ...